New antibody shows promise for thyroid eye disease in early trial

NCT ID NCT06226545

First seen Mar 21, 2026 · Last updated May 14, 2026 · Updated 10 times

Summary

This study tested a new drug called LASN01 in 41 adults with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. The drug aims to reduce eye bulging and inflammation by blocking a specific receptor. Participants received either LASN01 or a placebo to compare safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EYE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site 101

    San Diego, California, 92093, United States

  • Site 103

    Miami, Florida, 33136, United States

  • Site 104

    Houston, Texas, 77401, United States

  • Site 105

    Palo Alto, California, 94303, United States

  • Site 106

    Houston, Texas, 77030, United States

  • Site 108

    Livonia, Michigan, 48152, United States

  • Site 109

    Seattle, Washington, 98104, United States

  • Site 110

    Wilmington, North Carolina, 28403, United States

  • Site 111

    Beverly Hills, California, 90210, United States

  • Site 112

    Las Vegas, Nevada, 89144, United States

  • Site 201

    London, EC1V 2PD, United Kingdom

  • Site 204

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Site 206

    London, NW1 5QH, United Kingdom

  • Site 301

    Seville, 41009, Spain

  • Site 302

    Córdoba, 14012, Spain

Conditions

Explore the condition pages connected to this study.